Table 4.
Comparison of Efficacy and Adverse Events Between Two Treatments in Subgroups of Patients With Hemodynamically and Anatomically Massive PTE
| Hemodynamically Massive PTE |
Anatomically Massive PTE |
|||||
|---|---|---|---|---|---|---|
| rt-PA 100 mg | rt-PA 50 mg | P | rt-P 100 mg | rt-PA 50 mg | P | |
| Efficacy | ||||||
| Pulmonary artery obstruction score by CTPA | (n = 16) | (n = 16) | (n = 32) | (n = 39) | … | |
| Baseline | 26.5 ± 13.0 | 24.6 ± 10.9 | .652 | 28.2 ± 12.5 | 26.5 ± 12.3 | .572 |
| 24-hour | 15.9 ± 10.6 | 16.9 ± 8.7 | .787 | 19.6 ± 8.9 | 16.6 ± 8.7 | .157 |
| 14-day | 13.1 ± 11.8 | 11.6 ± 10.4 | .706 | 11.8 ± 8.8 | 9.2 ± 7.2 | .179 |
| Adverse events | (n = 19) | (n = 18) | … | (n = 34) | (n = 47) | … |
| Death | 1 (5) | 1 (6) | 1.000 | 2 (6) | 0 (0) | .417 |
| Due to PTE | 1 (5) | 0 (0) | … | 1 (3) | 0 (0) | … |
| Due to bleeding | 0 (0) | 1 (6) | … | 1 (3) | 0 (0) | … |
| Recurrent PTE | 1 (5) | 1 (6) | 1.000 | 1 (0) | 0 (0) | .418 |
| Bleeding complications | 7 (37) | 5 (28) | .728 | 10 (29) | 6 (13) | .090 |
| Major bleeding | … | … | 1.000 | 3 (9) | 0 (0) | .070 |
| Fatal bleeding | 0 (0) | 0 (0) | … | 1 (3) | 0 (0) | … |
| Others | 2 (11) | 2 (11) | … | 2 (6) | 0 (0) | … |
| Minor bleeding | 5 (26) | 3 (17) | .693 | 7 (21) | 6 (13) | .373 |
Data presented represent mean ± SD or number (%) of patients. CTPA = computed tomographic pulmonary angiography; Others = other major bleeding without death. See Table 1 for expansion of other abbreviations.